With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 ...

Merck KGaA is exercising its option for a global license to commercialize Abbisko Therapeutics Co. Ltd.’s pimicotinib for $85 million. As previously reported by BioWorld, Abbisko out-licensed China ...

SHANGHAI, China I March 31, 2025 I On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised ...

Merck paid Chinese biotech Abbisko Therapeutics $70 million upfront for rights to pimicotinib in China, Hong Kong, Macau, and Taiwan – with an option on rights for the rest of the world – last ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia.

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

(RTTNews) - Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of US$85.0 million ...

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of USD85.0 ...